Empowered Funds LLC Purchases New Shares in Danaher Corporation $DHR

Empowered Funds LLC purchased a new position in Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 39,911 shares of the conglomerate’s stock, valued at approximately $28,733,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. United Capital Financial Advisors LLC acquired a new stake in shares of Danaher in the second quarter valued at about $9,884,000. Grandeur Peak Global Advisors LLC purchased a new stake in shares of Danaher during the second quarter worth about $397,000. Bank OZK acquired a new position in shares of Danaher during the 2nd quarter worth about $9,226,000. Old North State Trust LLC acquired a new position in shares of Danaher during the 2nd quarter worth about $2,366,000. Finally, Equitable Holdings Inc. purchased a new position in Danaher in the 2nd quarter valued at about $3,015,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

NYSE DHR opened at $215.74 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock’s fifty day moving average is $198.69 and its two-hundred day moving average is $192.35. The firm has a market capitalization of $151.67 billion, a P/E ratio of 38.32, a price-to-earnings-growth ratio of 2.68 and a beta of 0.78. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period last year, the company earned $0.77 EPS. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Citigroup started coverage on Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price target on the stock. Royal Bank Of Canada boosted their price target on Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 22nd. Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Finally, TD Cowen decreased their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.